Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long Term Follow-up of Botox in Idiopathic Overactive Bladder
NCT00915525Phase 3Completed
- Sponsor
- Allergan
- Start
- Feb 2010
- Primary completion
- Aug 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 3, open-label trial of onabotulinumtoxinA in overactive bladder (OAB) and urinary incontinence (UI) (2 arms), sponsored by Allergan. Primary endpoints: Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes and Percentage of Patients With a Positive Response on the 4-Point Treatment Benefit Scale (TBS). Started Feb 2010; status: completed.
02
Drugs
onabotulinumtoxinA
03
Conditions
overactive bladder (OAB)urinary incontinence (UI)
Beyond the preview
Go deeper on NCT00915525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00915525.